The first therapeutic cancer vaccine has been approved in the US by the FDA, Dendreon's Provenge (sipuleucel-T). The long-awaited development will boost the field of cancer immunotherapy, a novel approach that stimulates the immune system to fight the disease.
Provenge is indicated for the treatment of asymptomatic or minimally symptomatic metastatic prostate cancer that is resistant to standard hormone treatment (hormone-refractory prostate cancer; HRPC)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?